{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:57:57Z","timestamp":1789567077156,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.clon.2024.03.020","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T16:23:13Z","timestamp":1710778993000},"page":"430-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systematic Review of Hypofractionated Radiation Therapy for the Treatment of Oesophageal Squamous Cell Carcinoma and Oesophageal Adenocarcinoma"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7060-442X","authenticated-orcid":false,"given":"C.","family":"Sanghera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"McClurg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4513-4964","authenticated-orcid":false,"given":"C.M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2024.03.020_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clon.2024.03.020_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global Burden of 5 Major Types of Gastrointestinal Cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clon.2024.03.020_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1759-7714.14745","article-title":"Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040","volume":"14","author":"Liu","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clon.2024.03.020_bib5","series-title":"Oesophageal cancer incidence statistics","year":"2015"},{"key":"10.1016\/j.clon.2024.03.020_bib6","article-title":"Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer","volume":"8","author":"Vellayappan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2024.03.020_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bjc.2017.21","article-title":"Long-term results and recurrence patterns from SCOPE-1: a phase II\/III randomised trial of definitive chemoradiotherapy +\/\u2212 cetuximab in oesophageal cancer","volume":"116","author":"Crosby","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2024.03.020_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2024.03.020_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002092.pub2","article-title":"Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus","author":"Wong","year":"2006","journal-title":"Cochrane Database Syst Rev CD002092"},{"key":"10.1016\/j.clon.2024.03.020_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13014-022-02099-y","article-title":"Dose escalation based on 18F-FDG PET\/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)","volume":"17","author":"Zhu","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib11","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ijrobp.2021.07.045","article-title":"Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2\/3 Randomized Trial CONCORDE (PRODIGE-26)","volume":"111","author":"Crehange","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.03.020_bib12","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102059","volume":"61","author":"Mukherjee","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clon.2024.03.020_bib14","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.20.03611","article-title":"Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial","volume":"39","author":"Goodman","year":"2021","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clon.2019.01.010","article-title":"Hypofractionated Radiotherapy in Oesophageal Cancer for Patients Unfit for Systemic Therapy: A Retrospective Single-Centre Analysis","volume":"31","author":"Jones","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000492","article-title":"Single modality radical radiotherapy is an acceptable alternative for the older patient with squamous cell carcinoma of the oesophagus","volume":"8","author":"Derby","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.clon.2024.03.020_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2468-1253(20)30007-8","article-title":"The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clon.2024.03.020_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2004.06.022","article-title":"Dose\u2013response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy","volume":"61","author":"Zhang","year":"2005","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib19","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0167-8140(05)80384-6","article-title":"223 Mature survival results with pre-operative hypofractionated radiotherapy with concurrent single cycle cisplatin and 5-fluorouracil chemotherapy for operable esophageal cancer","volume":"76","author":"Sahgal","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1442-2050.2006.00626.x","article-title":"Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas","volume":"19","author":"Miller","year":"2006","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.clon.2024.03.020_bib21","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.7314\/APJCP.2012.13.8.4163","article-title":"Moderately Hypofractionated Conformal Radiation Treatment of Thoracic Esophageal Carcinoma","volume":"13","author":"Ma","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clon.2024.03.020_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004591","article-title":"High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma","volume":"95","author":"Oh","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clon.2024.03.020_bib23","doi-asserted-by":"crossref","first-page":"S669","DOI":"10.1016\/S0167-8140(17)31677-8","article-title":"EP-1242: Palliative EBRT for incurable esophageal cancer and symptomatic dysphagia-single center results","volume":"123","author":"Yordanov","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx261.056","article-title":"057 - Preoperative short course radiotherapy for squamous cell carcinoma of esophagus revisited: Clinical profile and outcomes from tertiary care cancer centre","volume":"28","author":"Vinaya","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib25","doi-asserted-by":"crossref","first-page":"v12","DOI":"10.1093\/annonc\/mdy151.043","article-title":"P-044 - Long term survival in advanced esophageal cancer, treated with a French modality of hypofractionated radiotherapy + chemotherapy with or without surgery, the experience at the Instituto Nacional de Cancerolog\u00eda, M\u00e9xico","volume":"29","author":"Moreno","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib26","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/cam4.2250","article-title":"Comparison of efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma","volume":"8","author":"Lyu","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clon.2024.03.020_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/0284186X.2019.1670861","article-title":"Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial","volume":"59","author":"Borg","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2019.10.004","article-title":"Short-Course 2-Dimensional Radiation Therapy in the Palliative Treatment of Esophageal Cancer in a Developing Country: A Phase II Study (Sharon Project)","volume":"106","author":"Deressa","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib29","first-page":"1532","article-title":"Hypofractionated volumetric modulated arc therapy (VMAT) for fragile patients with oesophageal cancer","volume":"22","author":"Deantonio","year":"2020","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"10.1016\/j.clon.2024.03.020_bib30","doi-asserted-by":"crossref","first-page":"S1105","DOI":"10.1016\/S0167-8140(22)03274-1","article-title":"PO-1310 Frail and Elderly Patients with Oesophageal Cancer: the challenge of hypofractionated radiotherapy","volume":"170","author":"Deantonio","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13014-022-02127-x","article-title":"Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer","volume":"17","author":"Sridharan","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib32","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.clon.2022.09.028","article-title":"Single institution outcomes of conventional (1.8\u20132 Gy\/Fr) and hypofractionated (2.5\u20133 Gy\/Fr) RT in OG\/GOJ cancers during COVID-19","volume":"34","author":"Lee","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib33","article-title":"Moderately hypo-fractionated radiotherapy combined with S-1 in inoperable locally advanced esophageal squamous cell carcinoma: A prospective, single-arm phase II study (GASTO-1045)","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7785\/tcrt.2012.500176","article-title":"Phase I\/II Study of Hypofractioned Radiation with Three-dimensional Conformal Radiotherapy for Clinical T3-4N0-1M0 Stage Esophageal Carcinoma","volume":"10","author":"Song","year":"2011","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.03.020_bib35","doi-asserted-by":"crossref","first-page":"S1023","DOI":"10.1016\/S0167-8140(21)07691-X","article-title":"PO-1240 Complete pathological response after high dose radiotherapy for locally advanced esophageal cancer","volume":"161","author":"Hernando-Requejo","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.semradonc.2008.04.008","article-title":"Clinical experience using hypofractionated radiation schedules in breast cancer","volume":"18","author":"Whelan","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijrobp.2020.01.010","article-title":"Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer","volume":"107","author":"Vogelius","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.03.020_bib38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2007.03.046","article-title":"Moderately low alpha\/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy","volume":"69","author":"Suwinski","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2024.03.020_bib39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2006.01.009","article-title":"Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response","volume":"78","author":"Geh","year":"2006","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.clon.2024.03.020_bib40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524001158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524001158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T23:45:28Z","timestamp":1717285528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655524001158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0936655524001158"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2024.03.020","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Hypofractionated Radiation Therapy for the Treatment of Oesophageal Squamous Cell Carcinoma and Oesophageal Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2024.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}